Neoadjuvant Lenvatinib Plus Pembrolizumab Achieves Robust Pathological Complete Response in Resectable Merkel Cell Carcinoma
High Clinical Impact: Neoadjuvant Synergy in Merkel Cell Carcinoma
Highlights
The primary results of this investigator-initiated Phase II trial highlight three critical findings for the management of Merkel cell carcinoma (MCC):
1. A pathological complete response (pCR) rate of 57.7% was achieved with only six weeks of neoadjuvant lenvatinib and pembrolizumab.
2. The objective response rate (ORR) among radiographically evaluable patients reached 72.7%.
3. Progression-free survival (PFS) demonstrated a significant correlation with radiographic response, with a median PFS not yet reached at 20 months.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.